C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

Income Statement

Follow revenue through to earnings.

Revenue

$35.95M

FY 2025 · Annual

+1.0% YoY

Operating Income

-$104.49M

FY 2025 · Annual

Net Income

-$104.99M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.79M31.1M20.76M35.58M35.95M
Cost of Revenue007.74M07.98M
Gross Profit45.79M31.1M13.02M35.58M27.97M
Gross Margin100.0%100.0%62.7%100.0%77.8%
Research & Development94.67M117.84M117.71M110.64M104.24M
Selling, General & Admin33.25M42.79M42.08M42.12M36.2M
Operating Expenses127.92M160.63M152.05M155.2M132.46M
Depreciation & Amortization1.49M1.68M7.74M1.82M1.96M
EBITDA(80.26M)(124.28M)(122.1M)(103.37M)(102.91M)
EBITDA Margin-175.3%-399.7%-588.3%-290.5%-286.3%
Operating Income(82.13M)(129.53M)(139.03M)(119.61M)(104.49M)
Operating Margin-179.4%-416.6%-669.8%-336.1%-290.7%
Interest Income387K3.58M9.81M14.43M10.35M
Interest Expense2.15M2.22M1.37M00
Other Income / Expenses(1.76M)1.36M7.82M14.43M(384K)
Income Before Tax(83.89M)(128.18M)(131.21M)(105.19M)(104.87M)
Pre-Tax Margin-183.2%-412.2%-632.2%-295.6%-291.7%
Income Tax Expense001.28M131K121K
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Net Margin-183.2%-412.2%-638.3%-296.0%-292.1%
EPS (Basic)(1.82)(2.62)(2.67)(1.52)(1.27)
EPS (Diluted)(1.82)(2.62)(2.67)(1.52)(1.27)
Weighted Avg Shares46.04M48.86M49.64M69.37M82.89M
Weighted Avg Shares (Diluted)46.04M48.86M49.64M69.37M82.89M

CCCC Earnings Waterfall · TTM

NASDAQ:CCCC · Revenue to Net Income

Key Ratios

EPS$-1.19
Gross Margin92.7%
Net Margin-320.9%
P/E Ratio-2.1
P/S Ratio26.1

Analysis

$34.9M of revenue converted into -$103.8M of net income for the selected period. Gross margin is 92.7% and net margin is -320.9%, showing how much revenue survives after costs and taxes. EPS is $-1.19, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 2, 2026
4Statement of changes in beneficial ownershipOct 2, 2026

How much revenue does CCCC generate?

C4 Therapeutics, Inc. (CCCC) reported $35.95M of revenue in fiscal 2025.

Is CCCC profitable?

C4 Therapeutics, Inc. (CCCC) reported -$104.99M of net income, with a net margin of -292.1%.